Ribociclib vs Tibremciclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Ribociclib

Marketed by Novartis

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02422615 · Phase 3 · completed

The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.

Next expected readout: November 2026 · NCT02608216 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)

Result source: NCT02422615

Tibremciclib · Kangmeina

Marketed by Betta Pharmaceuticals Co.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05433480 · Phase 3 · status unknown

This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.

Result from the peer-reviewed publication (JAMA Oncology 2025); the registry has no posted results and its status is not updated.

Reported efficacy

Investigator-assessed PFS (up to 3 years): Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 (met)

Result source: NCT05433480

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointRibociclibTibremciclib
PFS, median20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results
—Not reported
OS, median63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result
—Not reported
ORR32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
—Not reported
Clinical benefit rate70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823
—Not reported

PFS, median

Ribociclib
20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results
Tibremciclib
—Not reported

OS, median

Ribociclib
63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result
Tibremciclib
—Not reported

ORR

Ribociclib
32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
Tibremciclib
—Not reported

Clinical benefit rate

Ribociclib
70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823
Tibremciclib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tibremciclib
Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 NCT05433480 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ribociclib: 4 of 4 rows · Tibremciclib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRibociclib
Dropout rate
n/a: no completion milestoneRibociclib + Fulvestranta
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneRibociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
59.9%
NCT02941926 · Phase 3 · combination
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePostmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePremenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.2%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
10.5%Ribociclib + Fulvestranta
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
4.8%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
11.4%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
15.5%
NCT02941926 · Phase 3 · combination
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
11.8%PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
6.5%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
1.3%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—Ribociclib + Fulvestranta
NCT02422615 · Phase 3 · combination
show 27 more results
37.1%Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
24.2%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
25%Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
32.3%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02941926 · Phase 3 · combination
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
29.4%PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
0%PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
27.3%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
17.7%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
6.7%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
neutropenia 57.8% (placebo 2.5%)
nausea 46.8% (placebo 31.1%)
diarrhoea 34% (placebo 22.4%)
NCT02422615 · Phase 3 · combination
show 18 more results
neutropenia 57.9% (placebo 6.5%)
arthralgia 38.8% (placebo 36.2%)
neutrophil count decreased 35.5% (placebo 1.5%)
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 75% (placebo 32.1%)
anaemia 50% (placebo 7.3%)
diarrhoea 50% (placebo 26.7%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 65.3% (placebo 5.5%)
nausea 54.8% (placebo 32.1%)
fatigue 43.4% (placebo 36.1%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 100% (placebo 23.4%)
white blood cell count decreased 100% (placebo 33.8%)
anaemia 94.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
aspartate aminotransferase increased 12.5% (placebo 40.3%)
blood alkaline phosphatase increased 6.3% (placebo 27.3%)
blood cholesterol increased 6.3% (placebo 16.9%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 85.7% (placebo 23.4%)
white blood cell count decreased 80.5% (placebo 33.8%)
anaemia 48.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
blood bilirubin increased 1.4% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 88.6% (placebo 23.4%)
white blood cell count decreased 87.3% (placebo 33.8%)
anaemia 55.7% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 2.7% (placebo 23.4%)
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
NCT03671330 · Phase 2 · registry result, not featured evidence
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
neutropenia 71.7% (placebo 15.3%)
fatigue 33.3% (placebo 32.2%)
aspartate aminotransferase increased 25% (placebo 28.8%)
NCT02632045 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ribociclib

PFS 21.8 vs 12.8 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 7 more results
20.5 vs 12.8 placebo months
NCT02422615 · Phase 3 · combination
NA vs 10.9 placebo months
NCT02422615 · Phase 3 · combination
23.8 vs 13 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
NA vs 14.7 placebo months
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
27.6 vs 14.7 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
NA vs 14.7 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
5.29 vs 2.76 placebo months
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Overall Survival NA vs NA Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 5 more results
NA vs 40 placebo months
NCT02422615 · Phase 3 · combination
NA vs 40.9 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
63.9 vs 51.4 placebo months
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.2 vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
NA vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
ORR 66.1% (n=112) vs 61.8% (n=110) Combination Chemotherapy600 mg
responder rate · % of participants
NCT03839823 · Phase 2 · registry result, not featured evidence
show 3 more results
32.4% (n=484) vs 21.5% (n=242) placebo
NCT02422615 · Phase 3 · combination
40.9% (n=335) vs 29.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.7% (n=334) vs 27.5% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 81.3% (n=112) vs 74.5% (n=110) Combination Chemotherapy600 mg
responder rate · % of participants
NCT03839823 · Phase 2 · registry result, not featured evidence
show 3 more results
70.2% (n=484) vs 62.8% (n=242) placebo
NCT02422615 · Phase 3 · combination
79.1% (n=335) vs 69.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.6% (n=334) vs 72.8% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 4 more results
NA vs NA placebo months
NCT02422615 · Phase 3 · combination
NA vs NA placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
3.6 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Duration of Response NA vs NA placebo months
time to event · months
NCT02422615 · Phase 3 · combination
show 3 more results
21.3 vs 17.5 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
37 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
45.2 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Time to Progression 27.1 months
time to event · months
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
ORR 45.3% (n=188)600 mg
responder rate · % of participants
No placebo or comparator arm
NCT03822468 · Phase 2 · registry result, not featured evidence
show 2 more results
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
29.3% (n=3246)
NCT02941926 · Phase 3 · combination
Clinical Benefit 70.7% (n=3246)
responder rate · % of participants
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
FACT-B 0.2 score @ 4wk
absolute change · score
No placebo or comparator arm
Cycle 2 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0.1 score @ 8wk
absolute change · score
No placebo or comparator arm
Cycle 3 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.3 score @ 12wk
absolute change · score
No placebo or comparator arm
Cycle 4 Day 1
NCT02941926 · Phase 3 · combination

+ 50 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ribociclib's landscape · Tibremciclib's landscape